Indeed, this has been found in previous studies using Tuba-seq in the context of EGFR inhibitors36 and chemotherapy59, provides a possible explanation of why many cancer therapies have low response rates, and suggests that matching patients to therapies based on both oncogene and tumor suppressor alterations may be critical to improving clinical outcomes. The gene discussed is EGFR; the disease is neoplasm.